Brief Article
Copyright ©2012 Baishideng.
World J Gastrointest Endosc. Sep 16, 2012; 4(9): 409-413
Published online Sep 16, 2012. doi: 10.4253/wjge.v4.i9.409
Table 1 Number of patients in each group of the study (control - antiplatelet group), the type of therapy, tumor, nodes and metastasis stage (1-4) in each group n (%)
No. of patientsTNM stage (mean ± SD)
Total387
Control group289 (74.6)2.57 ± 0.96
Antiplatelet group98 (25.4)2.27 ± 0.93
Aspirin652.19 ± 0.92
Clopidogrel17
Ticlopidid6
Dipyridamole4
Dual therapy6
Table 2 Incidence of colorectal cancer presenting symptoms and the distribution of cancer in the two groups of the study n (%)
Antiplatelet group (n = 98)Control group (n = 289)
Symptoms
Anemia43 (43.8)104 (35.9)
Blood loss per rectum28 (28.5)56 (19.3)
Obstruction/perforation15 (15.3)66 (22.8)
Altered bowel habits3 (3)29 (10)
Non-specific symptoms4 (4)18 (6.2)
Screening5 (5.1)16 (5.5)
Distribution
Right42 (42.8)116 (40.1)
Left33 (33.6)104 (35.9)
Rectum23 (23.4)69 (23.8)
Table 3 The incidence of each stage in each group (Antiplatelet and control group) and the comparison between the two groups n (%)
Antiplatelet group (n = 98)Control group (n = 289)P value
Stage I (1)24 (24.4)47 (16.2)0.0721
Stage II (2)32 (32.6)79 (27.3)0.3656
Stage III (3)34 (34.6)114 (39.3)0.4707
Stage IV (4)8 (8.1)49 (16.9)0.033